| Literature DB >> 35335044 |
Lídia Gual-Gonzalez1, Maggie S J McCarter1, Kyndall Dye-Braumuller1, Stella Self1, Connor H Ross1, Chloe Rodriguez-Ramos1, Virginie G Daguise1,2, Melissa S Nolan1.
Abstract
By the end of 2021, the COVID-19 pandemic resulted in over 54 million cases and more than 800,000 deaths in the United States, and over 350 million cases and more than 5 million deaths worldwide. The uniqueness and gravity of this pandemic have been reflected in the public health guidelines poorly received by a growing subset of the United States population. These poorly received guidelines, including vaccine receipt, are a highly complex psychosocial issue, and have impacted the successful prevention of disease spread. Given the intricate nature of this important barrier, any single statistical analysis methodologically fails to address all convolutions. Therefore, this study utilized different analytical approaches to understand vaccine motivations and population-level trends. With 12,975 surveys from a state-wide year-long surveillance initiative, we performed three robust statistical analyses to evaluate COVID-19 vaccine hesitancy: principal component analysis, survival analysis and spatial time series analysis. The analytic goal was to utilize complementary mathematical approaches to identify overlapping themes of vaccine hesitancy and vaccine trust in a highly conservative US state. The results indicate that vaccine receipt is influenced by the source of information and the population's trust in the science and approval process behind the vaccines. This multifaceted statistical approach allowed for methodologically rigorous results that public health professionals and policy makers can directly use to improve vaccine interventions.Entities:
Keywords: COVID-19; GIS; SARS-CoV-2; principal component analysis; survival analysis; vaccine hesitancy
Year: 2022 PMID: 35335044 PMCID: PMC8949372 DOI: 10.3390/vaccines10030412
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Vaccination rollout dates, corresponding pandemic phase, and the total number of doses administered including Pfizer-BioNTech and Moderna (first or completed doses), and J&J/Janssen (as complete dose): South Carolina, December 2020–December 2021. The information was obtained from the SC DHEC COVID-19 vaccine guidance and allocations data [14] and the Vaccination Dashboard [15].
Figure 2Demographics data and data process for each analysis.
Figure 3Unrotated component loadings. Variables with negative loadings are connected with a purple line, and variables with positive loadings are connected with a green line. The width of the line, along with the font size of the variable names, represents the strength of the relationship between the variables and the principal components. A list survey questions corresponding to each variable name can be found in the Supplementary Materials.
Logistic regression results of individual principal components and their relationship to receiving the COVID-19 vaccine.
| Principal Component | Short Description | OR | 95% Confidence INTERVAL | |
|---|---|---|---|---|
| PC1 | Vaccine mistrust | 0.50 | 0.45–0.58 | <0.001 |
| PC2 | Vaccine and government trust | 3.42 | 3.07–3.83 | <0.001 |
| PC3 | Mixed variables of uncertain significance | 1.04 | 0.90–1.21 | 0.6 |
| PC4 | Community, information, and risk factors | 1.03 | 0.88–1.22 | 0.7 |
Figure 4Kaplan-Meier survival curves demonstrating differences in receipt of vaccine for sociodemographic exposures: (a) age; (b) gender; (c) income; (d) race.
Hazard ratios (HRs) for vaccine receipt by cox proportional hazards model.
| Variable | Model 1 * | Model 2 † | Model 3 ‡ |
|---|---|---|---|
| ** | ** | ** | |
| 1.40 (1.24, 1.59) | 1.54 (1.31, 1.81) | 1.80 (1.39, 2.32) | |
| 60–70+ | 3.28 (2.90, 3.72) | 3.26 (2.78, 3.83) | 3.65 (2.83, 4.72) |
| Male | ** | ** | ** |
| 1.01 (0.97, 1.05) | 1.01 (0.95, 1.06) | 1.00 (0.93, 1.08) | |
| ** | ** | ** | |
| $35 K–$74,999 | 1.10 (1.02, 1.19) | 1.17 (1.05, 1.30) | 0.97 (0.84, 1.13) |
| 1.30 (1.21, 1.40) | 1.37 (1.25, 1.52) | 1.10 (0.95, 1.26) | |
| Prefer not to answer | 1.120 (1.035, 1.211) | 1.140 (1.027, 1.267) | 1.064 (0.919, 1.233) |
|
| |||
| White | ** | ** | ** |
| Black | 1.02 (0.94, 1.11) | 1.03 (0.93, 1.14) | 0.85 (0.73, 0.98) |
| Asian | 1.20 (1.03, 1.40) | 1.29 (1.01, 1.63) | 0.92 (0.65, 1.30) |
| Hispanic | 0.94 (0.81, 1.08) | 0.96 (0.80, 1.15) | 0.81 (0.62, 1.05) |
| Other | 0.66 (0.57, 0.75) | 0.60 (0.50, 0.72) | 0.75 (0.58, 0.98) |
|
| |||
| No | ** | ** | |
| Yes | 1.20 (1.13, 1.27) | 1.26 (1.17, 1.37) | |
|
| |||
| No | ** | ** | |
| Yes | 0.49 (0.46, 0.53) | 0.68 (0.62, 0.74) | |
|
| 0.99 (0.98, 1.00) | 0.98 (0.97, 0.99) | |
|
| |||
| No | ** | ||
| Yes | 4.61 (2.52, 8.40) | ||
| Not Sure | 2.49 (1.39, 4.44) | ||
|
| |||
| No | ** | ||
| Yes | 1.85 (1.12, 3.06) | ||
| Not Sure | 1.47 (0.90, 2.41) | ||
|
| |||
| No | ** | ||
| Yes | 1.80 (1.27, 2.55) | ||
| Not Sure | 1.69 (1.22, 2.35) | ||
|
| |||
| No | ** | ||
| Yes | 1.09 (1.00, 1.19) | ||
|
| |||
| No | ** | ||
| Yes | 2.43 (2.10, 2.82) | ||
|
| |||
| No | ** | ||
| Yes | 1.30 (1.17, 1.46) | ||
|
| |||
| No | ** | ||
| Yes | 3.23 (2.79, 3.73) | ||
|
| |||
| No | ** | ||
| Yes | 0.97 (0.86, 1.09) | ||
| Not Sure | 0.81 (0.70, 0.95) |
* Unadjusted model. † Adjusted for comorbid, BMI, ever tested positive for COVID-19. ‡ Adjusted for Model 2 covariates and think vaccines are safe, think vaccines are effective, trusts pharmaceutical research behind vaccines, got the vaccine to protect family or friend at high risk of disease, got the vaccine to protect self, got the vaccine to help control the pandemic, is a frontliner medical worker, think doctors have the best interest in patients when it comes to COVID-19. ** Reference level.
Figure 5Emerging hotspot analysis of COVID-19 vaccination status among South Carolina residents, between January 2021 and October 2021.
Figure 6Emerging hotspot analysis of COVID-19 vaccine perception among South Carolina residents, between January 2021 and October 2021.